Travere Therapeutics (TVTX) Other Non-Current Liabilities (2011 - 2026)
Travere Therapeutics' (TVTX) quarterly Other Non-Current Liabilities came in at $9.4 million in Q1 2026, up 28.92% YoY from $7.3 million in Q1 2025, and up 23.38% on a QoQ basis from $7.6 million in Q4 2025.
Travere Therapeutics (TVTX) Other Non-Current Liabilities (2011 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 16 years of Other Non-Current Liabilities data on file, last reported at $9.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 28.92% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 28.92% YoY) and the FY2025 annual result came in at $7.6 million, up 11.85% from the prior year.
- Other Non-Current Liabilities grew to $9.4 million in Q1 2026, from $7.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $76.2 million in Q3 2022 to a low of $5.9 million in Q3 2025.
- A 5-year average of $25.1 million and a median of $10.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
- The widest YoY moves for Other Non-Current Liabilities: up 626.57% in 2023, down 89.0% in 2023.
- Tracing TVTX's Other Non-Current Liabilities over 5 years: stood at $9.4 million in 2022, then gained by 9.96% to $10.3 million in 2023, then tumbled by 34.15% to $6.8 million in 2024, then gained by 11.85% to $7.6 million in 2025, then advanced by 23.38% to $9.4 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $9.4 million (Q1 2026), $7.6 million (Q4 2025), and $5.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.07 Mn |
| Mar 31, 2026 | 9.38 Mn |
| Dec 31, 2025 | 7.60 Mn |
| Sep 30, 2025 | 5.93 Mn |
| Jun 30, 2025 | 7.88 Mn |
| Mar 31, 2025 | 7.27 Mn |
| Dec 31, 2024 | 6.80 Mn |
| Sep 30, 2024 | 16.29 Mn |
| Jun 30, 2024 | 16.64 Mn |
| Mar 31, 2024 | 16.38 Mn |
| Dec 31, 2023 | 10.32 Mn |
| Sep 30, 2023 | 8.38 Mn |
| Jun 30, 2023 | 74.10 Mn |
| Mar 31, 2023 | 75.20 Mn |
| Dec 31, 2022 | 9.39 Mn |
| Sep 30, 2022 | 76.20 Mn |
| Jun 30, 2022 | 68.40 Mn |
| Mar 31, 2022 | 10.35 Mn |
| Dec 31, 2021 | 59.70 Mn |
| Sep 30, 2021 | 43.26 Mn |